Buy. The laboratory and testing specialist, which has only been included in Paris' leading index, the CAC40, since September, met expectations with its figures, but probably disappointed with its outlook. Nevertheless, growth is phenomenal and the P/E ratio for growth (30.9% in the first three months) is attractively low. Even without corona tests, there is a lot of fantasy here... only the dividend yield (0.7%) could be more attractive.